Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Buy RMD now and get great upside returns in a year or two, page-8
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.78 |
Change
-0.320(0.97%) |
Mkt cap ! $20.91B | |||
| Open | High | Low | Value | Volume |
| $32.74 | $33.07 | $32.74 | $34.25M | 1.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1267 | $32.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.82 | 2077 | 2 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.87 |
Change
-0.320 ( 0.67 %) |
||||
| Open | High | Low | Volume | ||
| $32.77 | $33.07 | $32.77 | 531228 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| RMD (ASX) Chart |